Clinical Trial Detail

NCT ID NCT03364348
Title 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors George W. Sledge Jr.
Indications

Her2-receptor positive breast cancer

Therapies

Trastuzumab + Utomilumab

Ado-trastuzumab emtansine + Utomilumab

Age Groups: adult senior

Additional content available in CKB BOOST